Doug Schenkel

Blair confirmed M&A readiness across all 3 segments with no segment-level constraints from the pending Masimo integration. Signaled both financial capacity and management bandwidth are available.

Gugino outlined 3 requirements for high-end attainment: further Life Sciences end market improvement, bioprocessing acceleration beyond high single digits in consumables plus equipment growth, and above-normal Q4 respiratory season back to ~$1.8B endemic rate.

Rainer confirmed improving M&A environment with better valuations and moderating interest rates. Balance sheet is prime for action. Maintaining disciplined framework but bias toward M&A remains strong.

Matt emphasized prudence, one quarter of growth is not a trend. Guiding flat for equipment as starting point. Will adjust as more data points confirm the trajectory.

Rainer confirmed improving tone in pharma discussions but not yet reflected in guidance, needs demonstrated order patterns before calling the trend. More confidence on tariffs and MFN becoming plannable.

Matt confirmed north of 100bps expansion is the right frame. $250M net savings drives $0.30 EPS tailwind. Company wants room to continue investing while delivering high-single-digit EPS growth.

Confirmed high-single-digit guide. H1 pricing 1.5-2%, similar or slightly better in H2. D&M slightly lower offset by better bioprocessing; full segment guide maintained.

Aldevron tracking as anticipated, expects improvement in H2 as comps ease. On EPS, $7.60-$7.75 includes cushion from remaining ~$100M of cost savings not yet in guide, balancing macro uncertainty.

Matt acknowledged EPS trajectory concern but defended bottom-up approach. Noted external headwinds were worked through and margin profile remained strong despite two down years.

Matt confirmed diagnostics ex-China is mid-to-high single-digits, in line with long-term aspiration. Headwinds are China VBP and respiratory normalization.

Padraig described steady to growing funnels. Reasonable budget flush in December, some intra-quarter disruption in Europe and weather in January. No deterioration in CapEx conditions. MFN deals reducing tariff uncertainty for pharma. Comprehensive.

Adam was deliberate: no arbitrary size filter but very high bar for transformative deals. Organic business is strong enough without transformation. Focused on strategic fit, right to win, integrability, and right price. Nice opportunities being evaluated.

Padraig attributed to US federal spending reductions. Americas instruments down mid-twenties, services/consumables resilient at low single digits. Ex US stable sequentially. No material government shutdown impact. Continued FY2026 softness expected. Direct.

Padraig quantified GLP-1 at ~$130M for FY2025, split evenly BioVectra/analytical lab. Q4 revenue ~$40M (60% BioVectra, 40% analytical). Analytical lab grew 40% on Alturo columns and Infinity 3. India as key generics opportunity. Very detailed.

Padraig stated very good Q4 visibility on orders, revenue, and margins. Positive momentum expected to continue into FY2026 but formal guidance deferred to next quarter. Direct.

Padraig emphasized Ignite as integration capability, M&A expected to be more meaningful going forward. Disciplined approach aligned to strategy pillars. Small list of high-quality targets. Also investing heavily in digital/CRM internally.

Padraig confirmed solid December driven by Infinity III, PFAS, GLP-1. January steady with only academia softness. PFAS business unchanged. Thorough.

Padraig openly confirmed wider error bars and intentional conservatism across China, LC replacement, and policy uncertainty. Transparent.

Bob explained NASD impact on biopharma numbers, volume dynamics in small molecule, and why it was first to recover. Detailed and analytical.

Ankur (answering Madeleine on for Doug) cited higher instrument mix, inflation and a full quarter of SomaLogic pressuring Q2, with mitigation benefits visible in H2.

Jacob reaffirmed the 2027 26% margin target and to get as close as possible including SomaLogic; Ankur confirmed the Q4 exit rate typically runs above the full-year 24.5%.

Jacob broadly endorsed the clinical-led framework without guiding, excluding China; Ankur pointed to further margin expansion from cost actions and operating leverage.

Jacob declined to give 2026 guidance but confirmed the X transition and clinical as the main drivers, with multiomics adding growth from 2026-2027.

Ankur quantified clinical consumables up mid-single digits and research down mid-to-high single digits, guiding research to a ~15% decline for the rest of the year.

Ankur pointed to 170bps of margin expansion in the base case plus additional earnings-growth opportunities, without ring-fencing China.

Shawn described a local Shanghai government grant encouraging capacity and research, split between CapEx and OpEx, excluded from free cash flow.

Shawn declined month-level detail, pointing back to the Q2 and full-year guidance by product area and region.

Patrick confirmed some budget flush activity with better momentum late in Q4. Beyond bioprocessing, LabX software solution driving automation of broader workflows in R&D and QA/QC labs. Digital capabilities and connectivity across lab portfolio creating competitive differentiation.

Shawn confirmed PA/bioprocessing was lab highlight plus power grid investments for data centers. Analytical instruments and weighing also grew well. Liquid handling soft spot. On industrial, transportation/logistics dynamic dimensioning contributed, timing skewed Q3 vs Q4. Q4 core industrial guided low single digit.

Patrick highlighted automation solution providers calling on MTD innovations across pharma, general manufacturing. Good momentum in US, China, and Asia Pacific.

Shawn acknowledged Europe upside potential offset by tougher Q4 comps. China remains wildcard, bouncing along bottom. Well positioned with China-for-China business but cautious H2 guide.

Max corrected China DX to ~6% of revenue. Expects DRG headwinds to continue until Q2 2026 anniversary, then low-single-digit growth per LRP. IDx ex-China up high single digits.

Prahlad noted annualization expected around late April 2026. IDx China now less than 6% of revenue, likely less than 5% in FY26.

Max confirmed normal Q3-to-Q4 seasonality with Genomics England ramp and larger Signals quarter in Q4.

Max confirmed China assumed in line with company at 3-5%, LS at higher end, Diagnostics at lower. Stimulus modest.

Prahlad provided clear breakdown: Diagnostics and software at normal, reagents getting closer, instruments still lagging.

Bob confirmed comfort with mid-to-high single digit revenue growth over the next several years, combining conservative GLP-1 assumptions with non-GLP-1 HVP recovery and Annex-1 tailwinds.

Bob confirmed no material pull-forward in Q3, noting Q4 is actually an acceleration on a 2-year stack. On visibility, emphasized improving transparency, deeper segment accountability, and closer customer engagement as reducing risk profile.

Bernard confirmed tariff guidance based on known rates at time of guidance, with Japan change not fully contemplated but immaterial. Eric expressed strong confidence in HVP momentum building but declined to comment specifically on 2026.

Bernard confirmed no SmartDose pricing or tariff pass-through embedded in guidance; both represent potential upside if materialized.

Eric confirmed GLP-1 is approximately 10% of total revenue, split roughly 40% of contract manufacturing and mid-single digits of proprietary.